Published in Oncogene on July 31, 2003
Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol (2011) 2.74
Tea polyphenols for health promotion. Life Sci (2007) 2.50
Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett (2008) 2.13
Perspectives for cancer prevention with natural compounds. J Clin Oncol (2009) 1.99
Green tea polyphenols for prostate cancer chemoprevention: a translational perspective. Phytomedicine (2010) 1.37
Cellular signaling perturbation by natural products. Cell Signal (2009) 1.36
Modulatory effects of polyphenols on apoptosis induction: relevance for cancer prevention. Int J Mol Sci (2008) 1.29
Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr Relat Cancer (2010) 1.26
Tea polyphenols, their biological effects and potential molecular targets. Histol Histopathol (2008) 1.26
Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol (2015) 1.24
Review: green tea polyphenols in chemoprevention of prostate cancer: preclinical and clinical studies. Nutr Cancer (2009) 1.22
Diet and prostate cancer: mechanisms of action and implications for chemoprevention. Nat Rev Urol (2010) 1.14
Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. Carcinogenesis (2011) 1.12
Green tea polyphenols and metabolites in prostatectomy tissue: implications for cancer prevention. Cancer Prev Res (Phila) (2010) 1.12
Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J (2010) 1.11
Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem (2011) 1.10
SHP-2 tyrosine phosphatase inhibits p73-dependent apoptosis and expression of a subset of p53 target genes induced by EGCG. Proc Natl Acad Sci U S A (2007) 1.07
Natural compounds with proteasome inhibitory activity for cancer prevention and treatment. Curr Protein Pept Sci (2008) 1.07
Chemopreventive effects of tea in prostate cancer: green tea versus black tea. Mol Nutr Food Res (2011) 1.06
Recent advances on tea polyphenols. Front Biosci (Elite Ed) (2012) 1.00
Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prev Res (Phila) (2010) 1.00
New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. Nutr Cancer (2011) 0.98
Green tea polyphenols as proteasome inhibitors: implication in chemoprevention. Curr Cancer Drug Targets (2011) 0.98
Lesson learned from nature for the development of novel anti-cancer agents: implication of isoflavone, curcumin, and their synthetic analogs. Curr Pharm Des (2010) 0.97
p53-Dependent p21-mediated growth arrest pre-empts and protects HCT116 cells from PUMA-mediated apoptosis induced by EGCG. Cancer Lett (2010) 0.96
Sinecatechins: Effects on HPV-Induced Enzymes Involved in Inflammatory Mediator Generation. J Clin Aesthet Dermatol (2012) 0.94
Molecular and cellular targets. Mol Carcinog (2006) 0.92
Radical decisions in cancer: redox control of cell growth and death. Cancers (Basel) (2012) 0.90
Green tea polyphenols increase p53 transcriptional activity and acetylation by suppressing class I histone deacetylases. Int J Oncol (2012) 0.90
Modulation of signaling pathways in prostate cancer by green tea polyphenols. Biochem Pharmacol (2012) 0.89
Tubeimoside-1 induces glioma apoptosis through regulation of Bax/Bcl-2 and the ROS/Cytochrome C/Caspase-3 pathway. Onco Targets Ther (2015) 0.89
Green tea and prostate cancer: from bench to clinic. Front Biosci (Elite Ed) (2009) 0.88
Effect of Sinecatechins on HPV-Activated Cell Growth and Induction of Apoptosis. J Clin Aesthet Dermatol (2012) 0.86
Green tea polyphenols induce p53-dependent and p53-independent apoptosis in prostate cancer cells through two distinct mechanisms. PLoS One (2012) 0.86
Epigallocatechin-3-gallate suppresses proinflammatory cytokines and chemokines induced by Toll-like receptor 9 agonists in prostate cancer cells. J Inflamm Res (2014) 0.86
In vitro and in vivo effects of water extract of white cocoa tea (Camellia ptilophylla) against human prostate cancer. Pharm Res (2010) 0.85
Complementary and alternative medicines in prostate cancer: from bench to bedside? Oncologist (2012) 0.85
Combination of NTP with cetuximab inhibited invasion/migration of cetuximab-resistant OSCC cells: Involvement of NF-κB signaling. Sci Rep (2015) 0.85
Anticancer activity of green tea polyphenols in prostate gland. Oxid Med Cell Longev (2012) 0.84
Insulin-like growth factor system in cancer: novel targeted therapies. Biomed Res Int (2015) 0.84
Implications of Green Tea and Its Constituents in the Prevention of Cancer via the Modulation of Cell Signalling Pathway. Biomed Res Int (2015) 0.84
Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment. Cancer Lett (2009) 0.83
Induction of cancer cell death by isoflavone: the role of multiple signaling pathways. Nutrients (2011) 0.83
Tea polyphenols inhibit cyclooxygenase-2 expression and block activation of nuclear factor-kappa B and Akt in diethylnitrosoamine induced lung tumors in Swiss mice. Invest New Drugs (2009) 0.82
Cyclin D1 degradation and p21 induction contribute to growth inhibition of colorectal cancer cells induced by epigallocatechin-3-gallate. J Cancer Res Clin Oncol (2012) 0.81
Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG). Nutr J (2016) 0.81
Modulation of inflammatory signaling pathways by phytochemicals in ovarian cancer. Genes Nutr (2011) 0.81
Regulation of p53-targeting microRNAs by polycyclic aromatic hydrocarbons: Implications in the etiology of multiple myeloma. Mol Carcinog (2014) 0.80
Recent progress on nutraceutical research in prostate cancer. Cancer Metastasis Rev (2014) 0.80
Green tea polyphenol, epigallocatechin-3-gallate, possesses the antiviral activity necessary to fight against the hepatitis B virus replication in vitro. J Zhejiang Univ Sci B (2014) 0.80
(-)-Epigallocatechin-3-gallate induces Du145 prostate cancer cell death via downregulation of inhibitor of DNA binding 2, a dominant negative helix-loop-helix protein. Cancer Sci (2009) 0.80
Dietary terpenoids and prostate cancer chemoprevention. Front Biosci (2008) 0.79
Sensitization to docetaxel in prostate cancer cells by green tea and quercetin. J Nutr Biochem (2015) 0.79
Chemoprevention of oral cancer: Green tea experience. J Nat Sci Biol Med (2014) 0.77
Crude drugs as anticancer agents. Int J Clin Exp Med (2010) 0.77
Anti-cancer potential of flavonoids: recent trends and future perspectives. 3 Biotech (2013) 0.77
Steep your genes in health: drink tea. Proc (Bayl Univ Med Cent) (2010) 0.76
Epigallocatechin gallate does not accelerate the early phase of liver regeneration after partial hepatectomy in rats. Dig Dis Sci (2013) 0.76
Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer. Oncotarget (2016) 0.75
KSHV-Mediated Regulation of Par3 and SNAIL Contributes to B-Cell Proliferation. PLoS Pathog (2016) 0.75
Epigallocatechin-3-gallate prevents autoimmune-associated down- regulation of p21 in salivary gland cells through a p53-independent pathway. Inflamm Allergy Drug Targets (2014) 0.75
Protective Effect of Green Tea (Camellia sinensis (L.) Kuntze) against Prostate Cancer: From In Vitro Data to Algerian Patients. Evid Based Complement Alternat Med (2017) 0.75
Green Tea Catechins for Prostate Cancer Prevention: Present Achievements and Future Challenges. Antioxidants (Basel) (2017) 0.75
Inhibitory effect of tea polyphenols on hepatic preneoplastic foci in Wistar rats. Invest New Drugs (2008) 0.75
Dose translation from animal to human studies revisited. FASEB J (2007) 15.67
Gene identification signature (GIS) analysis for transcriptome characterization and genome annotation. Nat Methods (2005) 7.87
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet (2010) 6.84
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med (2012) 4.22
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol (2008) 3.85
Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev (2007) 3.57
Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res (2006) 3.17
Transcriptome profiling of human and murine ESCs identifies divergent paths required to maintain the stem cell state. Stem Cells (2005) 3.16
ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med (2006) 2.86
IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity (2008) 2.78
Tea polyphenols for health promotion. Life Sci (2007) 2.50
Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal (2008) 2.36
Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett (2008) 2.13
Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis. Cell Cycle (2011) 2.12
Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer (2007) 2.00
Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of Wnt/β-catenin signaling and decreased Mitf levels. J Invest Dermatol (2011) 1.97
Apigenin and cancer chemoprevention: progress, potential and promise (review). Int J Oncol (2007) 1.91
S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9. Proc Natl Acad Sci U S A (2006) 1.87
Splenic arterial interventions: anatomy, indications, technical considerations, and potential complications. Radiographics (2005) 1.85
Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics (2005) 1.85
Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res (2004) 1.84
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res (2012) 1.83
An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry (2011) 1.80
Management of airway in patients with laryngeal tumors. J Clin Anesth (2005) 1.80
Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res (2008) 1.79
Apigenin: a promising molecule for cancer prevention. Pharm Res (2010) 1.78
Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci U S A (2005) 1.78
Curcumin for chemoprevention of colon cancer. Cancer Lett (2007) 1.75
Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol Biomarkers Prev (2007) 1.74
What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One (2011) 1.74
Dietary agents for chemoprevention of prostate cancer. Cancer Lett (2008) 1.72
Role of sonography in the diagnosis of gallbladder perforation. J Clin Ultrasound (2002) 1.70
Specific targeting of Wnt/β-catenin signaling in human melanoma cells by a dietary triterpene lupeol. Carcinogenesis (2010) 1.67
2013 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg (2013) 1.65
Restless legs syndrome in hemodialysis patients in India: a case controlled study. Sleep Med (2003) 1.64
Anthocyanin- and hydrolyzable tannin-rich pomegranate fruit extract modulates MAPK and NF-kappaB pathways and inhibits skin tumorigenesis in CD-1 mice. Int J Cancer (2005) 1.63
Ligand-dependent corepressor acts as a novel androgen receptor corepressor, inhibits prostate cancer growth, and is functionally inactivated by the Src protein kinase. J Biol Chem (2011) 1.60
CT-guided percutaneous fine-needle aspiration biopsy of small (< or =1-cm) pulmonary lesions. Radiology (2002) 1.59
Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res (2007) 1.58
Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. Oncogene (2002) 1.58
Botanical antioxidants in the prevention of photocarcinogenesis and photoaging. Exp Dermatol (2006) 1.57
Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin Cancer Res (2009) 1.57
Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia (2004) 1.56
High-fat diet activates pro-inflammatory response in the prostate through association of Stat-3 and NF-κB. Prostate (2011) 1.54
Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int J Oncol (2003) 1.53
IL-17 Expression by macrophages is associated with proliferative inflammatory atrophy lesions in prostate cancer patients. Int J Clin Exp Pathol (2011) 1.52
Apoptosis by dietary factors: the suicide solution for delaying cancer growth. Carcinogenesis (2006) 1.51
Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem (2006) 1.51
Gli2 is targeted for ubiquitination and degradation by beta-TrCP ubiquitin ligase. J Biol Chem (2006) 1.51
Transposon-based mutagenesis identifies short RIP1 as an activator of NFkappaB. Cell Cycle (2008) 1.49
A simplified method for preparation of 99mTc-annexin V and its biologic evaluation for in vivo imaging of apoptosis after photodynamic therapy. J Nucl Med (2003) 1.49
Delphinidin, an anthocyanidin in pigmented fruits and vegetables, protects human HaCaT keratinocytes and mouse skin against UVB-mediated oxidative stress and apoptosis. J Invest Dermatol (2006) 1.49
Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate (2005) 1.48
A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathways. Carcinogenesis (2008) 1.47
Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res (2005) 1.47
Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. J Biol Chem (2006) 1.47
Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem (2008) 1.46
Cannabinoids for cancer treatment: progress and promise. Cancer Res (2008) 1.46
A second mechanism for aluminum resistance in wheat relies on the constitutive efflux of citrate from roots. Plant Physiol (2008) 1.46
The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol (2006) 1.45
Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB J (2005) 1.45
Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res (2004) 1.45
Anterior cruciate ligament reconstruction: MR imaging signs of anterior knee laxity in the presence of an intact graft. Radiology (2012) 1.44
Molecular targets for green tea in prostate cancer prevention. J Nutr (2003) 1.43
Photochemoprevention of ultraviolet B signaling and photocarcinogenesis. Mutat Res (2005) 1.43
Transhepatic ipsilateral right portal vein embolization extended to segment IV: improving hypertrophy and resection outcomes with spherical particles and coils. J Vasc Interv Radiol (2005) 1.43
Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett (2003) 1.42
A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev (2006) 1.41
Antiproliferative and apoptotic effects of chamomile extract in various human cancer cells. J Agric Food Chem (2007) 1.41
Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res (2009) 1.40
Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J Clin Invest (2010) 1.40
p130/p107/p105Rb-dependent transcriptional repression during DNA-damage-induced cell-cycle exit at G2. J Cell Sci (2005) 1.39
Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins. Mol Cancer Ther (2006) 1.39
Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys (2003) 1.39
Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice. Cancer Res (2007) 1.38
Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int J Cancer (2005) 1.37
Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappa B and induction of apoptosis. Oncogene (2004) 1.36
Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells. Carcinogenesis (2008) 1.36
A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res (2008) 1.36
Lifestyle as risk factor for cancer: Evidence from human studies. Cancer Lett (2010) 1.35
Transhepatic portal vein embolization: anatomy, indications, and technical considerations. Radiographics (2002) 1.33
Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res (2007) 1.32
Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle (2007) 1.30
Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol (2006) 1.30